Birgitta Hiddinga

Birgitta Hiddinga is a researcher affiliated with the University of Groningen, focusing on oncology and immunotherapy. Her work emphasizes personalized medicine approaches in lung cancer treatment, including molecular diagnostics, targeted therapies, and immune checkpoint inhibition strategies. She completed her doctoral thesis in 2024 titled *Advances in personalized medicine for lung cancer: What's in it for the patient*, exploring patient-centered therapeutic innovations.

Her research spans immune-related side effects of cancer treatments (e.g., immune checkpoint inhibitor-mediated polymyalgia rheumatica), biomarker discovery for therapy response prediction, and optimization of bronchoscopy training programs through simulation-based methods. She collaborates with institutions like Barts Health (UK) and participates in interdisciplinary initiatives like the UMCG Molecular Tumor Board.

Recent activities include visiting lectureships at Merem Med Revalidatie and OLVG, presentations on bronchoscopy navigation techniques, and peer-review contributions. Though no explicit awards are listed, her work demonstrates significant engagement with translational oncology research and medical education.

Her advisory and grant activities are reflected in collaborative projects like the Molecular Tumor Board outcomes study, highlighting her role in bridging genomic research with clinical practice. She contributes to lung cancer treatment innovations through multidisciplinary teams at the UMCG.